COVID-19 Clinical Trial
Official title:
A Multicenter, Randomized, Single-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the Anti-COVID-19 Antibody SA55 for Injection in the Treatment of Patients With Hematological Disorders Who Are Persistently Positive for the Covid-19
This study is a multicenter, randomized, single-blind, placebo-controlled clinical trial to evaluate the effectiveness and safety of Anti-COVID-19 Antibody SA55 for Injection in patients with hematological malignancies. This study consists of two stages. In the first stage, 8 subjects aged 18-75 were recruited for safety assessment, including the monitoring of clinical test indicators and adverse events. After confirming the preliminary safety results of the first stage, we plan to recruit 160 COVID-19 patients with hematologic disorders aged 1-75 years old and randomly divided into the SA55 group and the placebo group with a ratio of 3:1. Basic information and laboratory tests will be collected during the whole study, and the occurrence of adverse events and SAEs of all subjects were collected.
Status | Recruiting |
Enrollment | 160 |
Est. completion date | May 31, 2024 |
Est. primary completion date | January 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year to 75 Years |
Eligibility | Inclusion Criteria: Subjects in this study must meet all of the following criteria: 1. Male or female patients with hematological malignancies who are in stable condition or with bone marrow failure disorders and aged from 1 to 75 years old on the day of enrollment; 2. On the day of enrollment, the subject was judged to be positive for Covid-19 nucleic acid/antigen for more than 10 days without turning negative or had turned negative but recovered positive again after 10 days; 3. On the day of enrollment, patients who have received CAR T-cell therapy, corticosteroids for a long time or other immuno-suppressive drugs, with the proportion of peripheral blood B cells is less than 2%; 4. Subjects (men and women with childbearing potential) and their sexual partners voluntarily take effective contraceptive measures from 4 weeks before screening to 3 months after the last dose of the test drug, and have no plan to donate sperm or eggs; 5. Subjects voluntarily participate in the trial and sign the informed consent form before the study begins. Exclusion Criteria: Those who meet any of the following conditions will be excluded: 1. Those who are known to be allergic to the test drug and any component in the preparation, or other similar drugs; 2. Complications requiring surgery within 7 days, or complication considered life-threatening within 28 days; 3. Received treatment with SARS-CoV-2 neutralizing antibody drugs before screening; 4. Convalescent plasma from recovered patients before screening; 5. Patients who took anti-SARS-CoV-2 drugs within 48 hours before enrollment, including but not limited to Paxlovid (Nirmatrelvir/Ritonavir), Azvudine, Molnupiravir, etc. 6. On the day of enrollment, meet the diagnostic criteria for severe/critical new coronavirus pneumonia; 7. Suspected to have been combined with active bacteria, fungi, viruses or other infections other than the new coronavirus; 8. Those who plan to become pregnant, are pregnant, or are breastfeeding; 9. Participated in clinical trials of SARS-CoV-2 neutralizing antibody drugs within 180 days before screening or participated in clinical trials of other drugs or medical devices within 4 weeks before screening; 10. Suffering from severe neurological diseases (epilepsy, convulsions or convulsions) or mental illness, with a family history of mental illness; 11. Suffering from other serious diseases that are not controlled, such as severe cardiovascular and cerebrovascular diseases, liver and kidney diseases, endocrine system diseases; or other diseases that the researchers judge are not suitable for participating in the study (such as currently uncontrolled autoimmune diseases, etc. ); 12. Other conditions that the researcher believes are not suitable for participating in this study due to various reasons. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Boren Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing Boren Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time when the subject has nucleic acid and the antigen test continues to turn negative | 21 days post intramuscular injection | ||
Secondary | Proportion of patients with negative persistent nucleic acid test(NAT)(key secondary endpoint) | 21 days post intramuscular injection | ||
Secondary | Change of CT value | 21 days post intramuscular injection | ||
Secondary | Proportion of Subjects Progressing to Severe/Critical | 21 days post intramuscular injection | ||
Secondary | Proportion of subjects who died from any cause | 21 days post intramuscular injection | ||
Secondary | Proportion of subjects admitted to ICU | 21 days post intramuscular injection | ||
Secondary | Number of days a case was admitted to the ICU | 21 days post intramuscular injection | ||
Secondary | Time of subject's shock correction | 21 days post intramuscular injection | ||
Secondary | Proportion of subjects requiring oxygen therapy | 21 days post intramuscular injection | ||
Secondary | Proportion of subjects requiring non-invasive ventilation | 21 days post intramuscular injection | ||
Secondary | Proportion of subjects requiring mechanical ventilation | 21 days post intramuscular injection | ||
Secondary | Days of subject's hospitalization from dosing | 21 days post intramuscular injection | ||
Secondary | Proportion of subjects with severe/critical illness or all-cause death related to COVID-19 | 21 days post intramuscular injection | ||
Secondary | The incidence of AEs | 21 days post intramuscular injection | ||
Secondary | The incidence of SAEs | 21 days post intramuscular injection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|